264 related articles for article (PubMed ID: 24752235)
1. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.
Al-Ejeh F; Simpson PT; Sanus JM; Klein K; Kalimutho M; Shi W; Miranda M; Kutasovic J; Raghavendra A; Madore J; Reid L; Krause L; Chenevix-Trench G; Lakhani SR; Khanna KK
Oncogenesis; 2014 Apr; 3(4):e100. PubMed ID: 24752235
[TBL] [Abstract][Full Text] [Related]
2. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
3. Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
Bonsang-Kitzis H; Sadacca B; Hamy-Petit AS; Moarii M; Pinheiro A; Laurent C; Reyal F
Oncoimmunology; 2016; 5(1):e1061176. PubMed ID: 26942074
[TBL] [Abstract][Full Text] [Related]
4. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
[TBL] [Abstract][Full Text] [Related]
5.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
6. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.
Callari M; Musella V; Di Buduo E; Sensi M; Miodini P; Dugo M; Orlandi R; Agresti R; Paolini B; Carcangiu ML; Cappelletti V; Daidone MG
Mol Oncol; 2014 Oct; 8(7):1278-89. PubMed ID: 24853384
[TBL] [Abstract][Full Text] [Related]
7. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
Bianchini G; Qi Y; Alvarez RH; Iwamoto T; Coutant C; Ibrahim NK; Valero V; Cristofanilli M; Green MC; Radvanyi L; Hatzis C; Hortobagyi GN; Andre F; Gianni L; Symmans WF; Pusztai L
J Clin Oncol; 2010 Oct; 28(28):4316-23. PubMed ID: 20805453
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
Vishnubalaji R; Alajez NM
Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.
Kaur P; Nagaraja GM; Zheng H; Gizachew D; Galukande M; Krishnan S; Asea A
BMC Cancer; 2012 Mar; 12():120. PubMed ID: 22452810
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
[TBL] [Abstract][Full Text] [Related]
11. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
12. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
Angajala A; Mothershed E; Davis MB; Tripathi S; He Q; Bedi D; Dean-Colomb W; Yates C
Transl Oncol; 2019 Mar; 12(3):493-501. PubMed ID: 30594038
[TBL] [Abstract][Full Text] [Related]
13. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.
Jadaliha M; Zong X; Malakar P; Ray T; Singh DK; Freier SM; Jensen T; Prasanth SG; Karni R; Ray PS; Prasanth KV
Oncotarget; 2016 Jun; 7(26):40418-40436. PubMed ID: 27250026
[TBL] [Abstract][Full Text] [Related]
14. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
[TBL] [Abstract][Full Text] [Related]
15. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
17. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
20. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
